Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing Strategies

Set Alert for Pricing Strategies

Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing

Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.

Pricing Strategies Legal Issues

June Sees UK Ivabradine Prices More Than Treble

Ivabradine exhibited interesting pricing dynamics in the UK in June, with the average cost of the heart failure treatment more than trebling despite the lowest offer in the market remaining stable.

Market Intelligence Pricing Strategies

BGMA Emphasizes Benefits Of Competition After UK Hydrocortisone Fines

UK off-patent industry association the BGMA has responded to recent fines issued by competition regulator the CMA over illegal deals for hydrocortisone, highlighting the benefits of functioning generic competition as well as urging improvements to the UK’s pricing and reimbursement system to better recognize situations where supply is limited.

Pricing Strategies Regulation

Firms Vow To Appeal After CMA’s £260m Hydrocortisone Fines In UK

Firms censured by the UK’s CMA competition regulator over illegal deals that drove up the price of hydrocortisone for around a decade have vowed to appeal against the decision and the imposition of fines totaling more than £260m.

United Kingdom Legal Issues

AAM Strengthens Calls For Reforms To Stop Anticompetitive Tactics

The US Association for Accessible Medicines discussed six areas for reform during a recent US Senate Judiciary Committee hearing “shining a spotlight on the anti-competitive tactics used by some brand name pharmaceutical companies to delay patient access” to generics and biosimilars.

Policy Regulation

Valeo Expects Full Enoxaparin Biosimilar Coverage By Year End

Canadian firm Valeo Pharma revealed the extent of coverage for its Lovenox biosimilars, months after launching the low molecular weight heparin in-licensed from Shenzhen Techdow Pharmaceutical.

Biosimilars Reimbursement

Amgen’s Bevacizumab Biosimilar Is Alone On Australia’s PBS

US-based giant Amgen has seen its Mvasi biosimilar become the sole bevacizumab product listed on Australia’s Pharmaceutical Benefits Scheme.

Biosimilars Generic Drugs

Medicare Is Overpaying For Generics, Says JAMA Study

A study published in the Journal of the American Medical Association has found that while Medicare coverage of generic drugs likely improves patient adherence and reduces other health care utilization, inefficiencies stemming from its “complex and opaque system of intermediaries” mean that it has overpaid on most prescription generics compared to retailer Costco. 

United States Generic Drugs

AAM Sees Extended Support For BIOSIM Act

US representatives Kurt Schrader and Adam Kinzinger have introduced the BIOSIM Act to improve access and realize the full potential of biosimilars by encouraging an additional payment for providers when they use a biosimilar cheaper than the reference biologic. AAM and a group of organizations have extended support to the bipartisan bill. 

United States Biosimilars
See All
UsernamePublicRestriction

Register

;